Research Article
Synthesis and Anticancer Activity of N-Aryl-5-substituted-1,3,4-oxadiazol-2-amine Analogues
Table 3
In vitro anticancer activity of N-aryl-5-substituted-1,3,4-oxadiazol-2-amine analogues (4a–x).
| | Compound | 60 cell lines assay in one dose 10−5 M conc. | | NSC Code | Mean GP | Range of GP | The most sensitive cell lines | GP of the most sensitive cell lines |
| | 4a | 776721 | 98.88 | 72.88 to 114.64 | NCI-H522 (non-small-cell lung cancer)
SNB-75 (CNS cancer)
MCF7 (breast cancer)
A498 (renal cancer) | 72.88
80.44
83.98
85.88 |
| | 4b | 776720 | 102.09 | 84.59 to 123.42 | A498 (renal cancer)
T-47D (breast cancer)
UO-31 (renal cancer)
MCF7 (breast cancer) | 84.59
86.46
92.10
92.37 |
| | 4c | 777952 | 98.55 | 76.67 to 117.71 | SR (leukemia)
K-562 (leukemia)
HL-60 (TB) (leukemia)
SNB-75 (CNS cancer) | 76.67
81.05
82.02
83.85 |
| | 4d | 776719 | 100.71 | 83.46 to 127.18 | UO-31 (renal cancer)
MDA-MB-231/ATCC (breast cancer)
SK-OV-3 (ovarian cancer)
MCF7 (breast cancer) | 83.46
86.63
89.42
89.92 |
| | 4e | 776722 | 100.59 | 80.87 to 117.08 | HOP-92 (non-small-cell lung cancer)
UO-31 (renal cancer)
HL-60 (TB) (leukemia)
NCI-H522 (non-small-cell lung cancer) | 80.87
83.10
87.92
88.13 |
| | 4f | 777951 | 98.50 | 65.75 to 110.26 | SR (leukemia)
MOLT-4 (leukemia)
UO-31 (renal cancer)
HCT-116 (colon cancer) | 65.75
82.58
87.20
88.20 |
| | 4h | 776724 | 97.30 | 60.45 to 111.98 | SK-MEL-2 (melanoma)
MDA-MB-231/ATCC (breast cancer)
UO-31 (renal cancer)
MCF7 (breast cancer) | 60.45
67.42
80.02
82.97 |
| | 4i | 777954 | 97.93 | 75.33 to 118.40 | HL-60 (TB) (leukemia)
K-562 (leukemia)
SR (leukemia)
NCI-H522 (non-small-cell lung cancer) | 75.33
81.88
85.63
88.68 |
| | 4j | 776723 | 97.03 | 75.06 to 120.27 | HOP-92 (non-small-cell lung cancer)
MOLT-4 (leukemia)
NCI-H522 (non-small-cell lung cancer)
SNB-75 (CNS cancer) | 75.06
76.31
79.42
81.73 |
| | 4k | 776725 | 97.80 | 73.29 to 116.30 | PC-3 (prostate cancer)
UO-31 (renal cancer)
MOLT-4 (leukemia)
HOP-92 (non-small-cell lung cancer) | 73.29
82.21
83.75
84.14 |
| | 4l | 777953 | 97.10 | 76.62 to 112.24 | A498 (renal cancer)
MALME-3M (melanoma)
MOLT-4 (leukemia)
SR (leukemia) | 76.62
77.96
79.51
82.94 |
| | 4m | 776715 | 101.09 | 79.80 to 128.96 | A498 (renal cancer)
SK-MEL-2 (melanoma)
HL-60 (TB) (leukemia)
MCF7 (breast cancer) | 79.80
80.78
80.81
81.12 |
| | 4n | 776716 | 100.42 | 59.21 to 116.24 | SK-MEL-2 (melanoma)
UO-31 (renal cancer)
MOLT-4 (leukemia)
BT-549 (breast cancer) | 59.21
82.84
84.21
86.27 |
| | 4s | 777948 | 62.61 | 15.43 to 88.49 | MDA-MB-435 (melanoma)
K-562 (leukemia)
T-47D (breast cancer)
HCT-15 (colon cancer) | 15.43
18.22
34.27
39.77 |
| | 4u | 777949 | 78.46 | 6.82 to 106.57 | MDA-MB-435 (melanoma)
K-562 (leukemia)
NCI-H522 (non-small-cell lung cancer)
HCT-15 (colon cancer) | 6.82
24.80
41.03
44.74 |
| | 4w | 777950 | 101.29 | 80.97 to 115.23 | T-47D (breast cancer)
A498 (renal cancer)
HCT-116 (colon cancer)
UO-31 (renal cancer) | 80.97
87.44
89.01
90.55 |
|
|
